[ad_1]
WASHINGTON — Food and Drug Administration Authorized support shots on Wednesday For tens of millions of recipients of Moderna’s two-dose coronavirus vaccine and Johnson & Johnson’s single-dose vaccine, it significantly expands its efforts to support protection for vulnerable Americans.
The agency also provides medical providers with a additional insignia of a different Covid-19 vaccine, a strategy known as “Mix and Match.”
This decision could dampen interest in the United States’ vaccine, which Johnson & Johnson has found to offer less protection than the other two. Recipients of this vaccine will have the option to search for a Moderna or Pfizer-BioNTech booster, which could lead to a more significant jump in protective antibodies. Recipients of the other two vaccines will have the same freedom to choose a different vaccine for the booster vaccine.
Regulators that allowed boosters for high-risk recipients of the Pfizer-BioNTech vaccine last month did not recommend any vaccine as a booster over the other.
Acting commissioner of the FDA, Dr. “We don’t have preferential recommendations,” Janet Woodcock said at an evening news briefing. “We think that if patients have questions, maybe they should consult their doctor or another provider.”
The latest permits came in the midst of what is shaping up to be a dense extension of key regulatory decisions regarding vaccines. The FDA is expected to decide in the coming weeks whether to approve Pfizer-BioNTech’s vaccine for children ages 5 to 11. The agency’s independent vaccine advisory committee will consider the matter Tuesday and make a recommendation.
Regulators may also decide in early November whether to allow more people to receive booster vaccines, including young adult recipients of not yet eligible Pfizer or Moderna vaccines. While many vaccine experts are currently questioning whether healthy teens need booster vaccines, some members of the advisory board last week urged the agency to expand eligibility.
As the FDA’s top vaccine regulator, Dr. Peter Marks said the institution could be “agile” in involving younger adults. “This is something that can happen as soon as we see and feel the need to take action,” he said.
One of the key questions before regulators was whether a full or half dose of Moderna’s vaccine should be approved as a booster shot. Data from a federally funded study suggested that a full dose of Moderna could greatly increase the antibody levels of Johnson & Johnson recipients and better increase the antibody levels of Pfizer recipients than an additional shot of the same vaccine.
However, Moderna only asked permission for half a dose as a booster shot and submitted data to support it. Finally, the FDA, to limit confusion among providers, Dr. He decided to authorize half a dose of the Moderna booster for recipients of all three vaccines, as Marks suggested.
A move to qualify a much larger group of Americans for boosters followed Wednesday. consensus vote to recommend authorizations from the FDA advisory committee last week. A separate committee that advises the Centers for Disease Control and Prevention is scheduled to vote on its own recommendations for Moderna and Johnson & Johnson boosters on Thursday.
The panel will also consider whether people need more guidance on when and when to switch vaccines for a booster shot. CDC officials are expected to argue for flexibility.
Dr. Given the available data, “we have to be unbiased about what’s best,” said Marks. “We have to say that any of these combinations are reasonable.”
The CDC’s director typically approves this panel’s recommendations as a final step before vaccines are introduced. If the agency agrees with the FDA, these booster shots could be available to the public as soon as this weekend.
Eligibility requirements for a booster differ depending on the vaccine. Pfizer and Moderna recipients will be able to receive an extra vaccine six months after the second injection if they are at least 65 years old or at high risk for serious Covid-19 complications due to their medical condition or workplace. Johnson & Johnson recipients, all 18 years of age or older, will be eligible for a second shoot at least two months after the first.
The decision to allow recipients to switch to a different vaccine as a booster adds another layer of complexity. “Although it’s not simple,” said Dr. Marks, “not completely hopelessly complicated.”
While the FDA advisory panel unanimously supported the Moderna and Johnson & Johnson boosters last week, its experts expressed concerns that data on companies’ applications is limited and has not been independently verified in Johnson & Johnson’s case.
Moderna argued to the committee that the third shot of its vaccine would increase protection against infection and milder diseases. There seemed to be little evidence that the vaccine’s potent protection was significantly diminished.
In response, some FDA experts and committee members have argued that Johnson & Johnson recipients need an additional vaccine to better support them against severe Covid-19, as the vaccine is less effective than Moderna and Pfizer-BioNTech.
The FDA discussed data with the committee showing that Johnson & Johnson’s vaccine was only roughly 70 percent effective against hospitalization, compared to nearly 90 percent for Moderna and Pfizer.
But other dataIncluding a study of nearly nine million people in New York State, including older Americans, a single dose of Johnson & Johnson achieved better results and provided durable protection.
What You Need to Know About Covid-19 Booster Shots
The FDA has allowed booster shots for millions of buyers. Pfizer-BioNTech, modern and Johnson and Johnson vaccines. Pfizer and Moderna recipients who qualify for support include people aged 65 and over and young adults at high risk of serious Covid-19 due to medical conditions or where they work. Eligible Pfizer and Moderna recipients can receive a boost for at least six months after their second dose. All Johnson & Johnson recipients will be eligible for a second shoot at least two months after the first.
Yeah. The FDA has updated its mandate to allow medical providers to empower people with a different vaccine than the one they originally received. “Mix and Match.” You can get a booster for any other vaccine, whether you’ve received Moderna, Johnson & Johnson, or Pfizer-BioNTech. The regulators did not recommend any vaccine over the other as a booster. They also remained silent on whether it would be preferable to stick to the same vaccine whenever possible.
The CDC said conditions that qualify a person for a booster shot include: hypertension and heart disease; diabetes or obesity; cancer or blood diseases; weakened immune system; chronic lung, kidney, or liver disease; dementia and some disabilities. Pregnant women and current and former smokers are also eligible.
The FDA has allowed boosters for workers whose jobs put them at risk of exposure to potentially infectious humans. The CDC says the group includes: emergency health workers; education workers; food and agricultural workers; manufacturing workers; correction workers; US Postal Service employees; public transport workers; grocery workers.
Yeah. The CDC says the Covid vaccine can be administered regardless of the timing of other vaccines, and many pharmacy sites allow people to schedule a flu shot at the same time as a booster dose.
Experts have taken to the idea that a single shot of Johnson & Johnson’s vaccine has never provided as much protection as vaccines from Moderna and Pfizer-BioNTech and should therefore be supplemented. They also argued that Moderna buyers should be eligible for backing shots, at least in part because Pfizer buyers already exist. Pfizer received authorization for a booster vaccine last month after claiming that its vaccine had diminished effectiveness against severe diseases.
University of Iowa infectious disease specialist and FDA committee member Dr. “We’ve already approved for Pfizer, and I don’t see how we can’t approve for Moderna,” Stanley Perlman said. .
Norman W. Baylor, former director of the FDA’s vaccines office, questioned why the FDA forced a committee of experts to convene a vote on booster vaccines, saying the lack of verified data for Johnson & Johnson’s vaccine was extremely unusual.
“It’s clear the FDA isn’t prepared,” he said. “From what we’ve seen, the FDA appears to be in a rush to make a decision on these boosters.”
After the Biden administration began pushing for a broad rollout of support in August, senior officials said simplifying accelerator recommendations could help avoid public confusion. Dr. Marks said the goal is to reach a “coherent” approach to supportive recommendations for the general population.
For at least some of the nearly 15 million people who choose the Johnson & Johnson vaccine, the controversy over the company’s data may not be significant. The FDA’s decision to provide flexibility to providers and patients with booster shots may lead many to choose a Moderna or Pfizer-BioNTech booster instead.
The regulators were impressed by preliminary data from a federally funded study that measured antibody levels in people who received a different vaccine as a booster and compared nine groups of 50 volunteers each. In the study, those who received another dose of Johnson & Johnson only saw their antibodies increase fourfold. Switching to the Pfizer-BioNTech booster increased antibody levels 35-fold. A full dose of the Moderna booster increased them 76 times.
Presenting the findings at the FDA meeting last week, Dr. Kirsten E. Lyke warned in an interview against drawing hasty conclusions from her conclusions. By next month, the researchers hope to know how well different boosters boost T cells that attack the virus. It’s possible that Johnson & Johnson’s vaccine will succeed with these results, he said, adding, “We’re going to get a more comprehensive picture.”
Since the Pfizer-BioNTech vaccine was approved as a booster vaccine last month, some state health officials have clamored for mix-and-match flexibility, saying it will help them reach older and at-risk residents in the absence of the vaccine. it’s the same vaccine that people get initially.
Senior CDC officials suggested last week that the mix-and-match rules would make room for those concerned about side effects—young women, for example, concerned about the links of the Johnson & Johnson vaccine to a rare blood clotting condition—to switch brands. On the other hand, some may be interested in switching to Johnson & Johnson if they are concerned about rare heart-related side effects associated with the Moderna and Pfizer-BioNTech vaccines.
Dr. “We would expect a lot of people to continue buying the series they bought before,” Woodcock said. But he added: “We wanted to provide a lot of flexibility.”
Carl Zimmer Conn contributed reporting from New Haven, Conn.
[ad_2]
Source link